Document is current

Article History

Received: 30 November 2023

Revised: 4 March 2024

Accepted: 5 March 2024

First Online: 26 March 2024

Declarations

:

: GM, OF, and LS no competing interests are disclaimed. RB has served on scientific advisory boards and received funding for travel, speaker honoraria, research support from Almirall, Bayer, Biogen, Bristol Myers Squibb/Celgene, Janssen, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. MPA has served on Scientific Advisory Boards for Biogen, Novartis, Roche, Merck, Sanofi Genzyme and Teva; has received speaker honoraria from Biogen, Merck, Sanofi Genzyme, Roche, Novartis, and Teva; has received research grants for her Institution from Biogen, Merck, Sanofi Genzyme, Novartis and Roche, Italian MS Foundation, Canadian MS Foundation, Italian Health Ministry, Regione Toscana. She is co-Editor of the Multiple Sclerosis Journal. MT has served on Scientific Advisory Boards for Biogen, Novartis, Roche, Merck, BMS Celgene, and Janssen; has received speaker honoraria from Biogen, Sanofi, Merck, Roche, and Novartis; and has received research grants for her Department from Biogen, Merck, Roche, and Novartis. MZ has received travel support, speaking honoraria or served on advisory boards for Alexion, Biogen, BMS-Celgene, Janssen-Cilag, Novartis, Merck, Roche, and Sanofi. CM, AS, EC, ER, EP, LR, PI, and DP report no disclosures relevant to this manuscript.

: Not required.